Pre-clinical investigation of liquid sirolimus for local drug delivery

被引:3
|
作者
Todd, Meagan [1 ]
Liu, Linda B. [1 ]
Saul, Justin M. [2 ]
Yazdani, Saami K. [1 ]
机构
[1] Wake Forest Univ, Dept Engn, Winston Salem, NC 27109 USA
[2] Miami Univ, Dept Chem Paper & Biomed Engn, Oxford, OH USA
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2023年 / 10卷
关键词
sirolimus; liquid; ex vivo; pharmacokinetics; drug delivery; peripheral arterial disease; delivery device; BALLOON; PACLITAXEL; ANGIOPLASTY; RESTENOSIS; REGULATORS; RESPONSES; RAPAMYCIN; MODEL;
D O I
10.3389/fcvm.2023.1184816
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Sirolimus is currently being explored as an alternative drug to paclitaxel for the treatment of peripheral artery disease (PAD). To date, sirolimus has only been used as drug coatings for stents and balloons and no studies have yet demonstrated the delivery of sirolimus in liquid form. The purpose of this pilot study was to investigate the feasibility of the delivery of liquid sirolimus into arterial segments in a benchtop peripheral artery bioreactor.Methods: The feasibility to deliver liquid therapy was first tested on four drug delivery devices using a fluorescently tagged liquid drug and an ex vivo porcine artery benchtop model. The four devices included the Bullfrog micro-infusion device, ClearWay RX catheter, Occlusion perfusion catheter (OPC), and the targeted adjustable pharmaceutical administration system (TAPAS). Penetration of the fluorescently tagged drug was measured via microscopic imaging and quantification of the depth of drug penetration into all device-treated tissue. Based on the penetration outcome, we then selected a single device to deliver liquid sirolimus into the ex vivo porcine artery model undergoing physiological flow and pressure conditions. The liquid sirolimus-treated arteries were collected from the ex vivo bioreactor at 1- and 24-hour post-delivery and arterial drug retention analyzed by liquid chromatography-tandem mass spectrometry.Results: Fluorescent microscopy demonstrated that drug delivery with the OPC had greater drug penetration into the medial wall as compared to other devices (OPC: 234 +/- 161 mu m; TAPAS: 127 +/- 68 mu m; ClearWay: 118 +/- 77 mu m; Bullfrog: 2.12 +/- 3.78 mu m; p = 0.098). The results of the ex vivo flow-circuit bench top model showed that the OPC device successfully delivered the liquid sirolimus at 1-hour (5.17 +/- 4.48 ng/mg) and 24-hour (0.78 +/- 0.55 ng/mg).Conclusions: These results demonstrate for the first time the ability to deliver liquid sirolimus directly to the medial layer of an artery via a liquid delivery catheter.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations
    Abduelkarem, Abduelmula R.
    Anbar, Hanan S.
    Zaraei, Seyed-Omar
    Alfar, Aya A.
    Al-Zoubi, Omayma S.
    Abdelkarem, Eveen G.
    El-Gamal, Mohammed I.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 188
  • [32] Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence
    Qin, Yi
    Ashrafizadeh, Milad
    Mongiardini, Vera
    Grimaldi, Benedetto
    Crea, Francesco
    Rietdorf, Katja
    Gyorffy, Balazs
    Klionsky, Daniel J.
    Ren, Jun
    Zhang, Wei
    Zhang, Xianbin
    CANCER LETTERS, 2023, 570
  • [33] Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization
    Glueck, R
    VACCINE, 2001, 20 : S42 - S44
  • [34] Pre-clinical investigation of a novel investigational new drug, SHetA2, for the treatment of vulvar cancer
    Duininck, Grace
    Garland, Justin
    Lausen, James
    Mortan, Laura
    Bohn, Jacqueline
    Benbrook, Doris
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S230 - S231
  • [35] Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
    Weeber, Fleur
    Ooft, Salo N.
    Dijkstra, Krijn K.
    Voest, Emile E.
    CELL CHEMICAL BIOLOGY, 2017, 24 (09): : 1092 - 1100
  • [36] Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis
    Margaryan, Hasmik
    Evangelopoulos, Dimitrios D.
    Wildner, Leticia Muraro
    McHugh, Timothy D.
    MICROORGANISMS, 2022, 10 (03)
  • [37] Zebrafish As a Genetic Model in Pre-Clinical Drug Testing and Screening
    Gibert, Y.
    Trengove, M. C.
    Ward, A. C.
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (19) : 2458 - 2466
  • [38] PRE-CLINICAL AND CLINICAL BIOCHEMISTRY
    GONDWE, ATD
    BIOCHEMICAL EDUCATION, 1985, 13 (01): : 19 - 21
  • [39] PRE-CLINICAL REFINEMENT OF A HIGHLY-PENETRATIVE POLYMERIC NANOPARTICLE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME
    Strohbehn, Garth
    Atsina, Komli-Kofi
    Patel, Toral
    Piepmeier, Joseph
    Zhou, Jiangbing
    Saltzman, W. Mark
    NEURO-ONCOLOGY, 2013, 15 : 59 - 59
  • [40] Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation
    Mihaylov, Ivaylo B.
    Totiger, Tulasigeri M.
    Giret, Teresa M.
    Wang, Dazhi
    Spieler, Benjamin
    Welford, Scott
    PLOS ONE, 2021, 16 (08):